DURECT (NASDAQ:DRRX) Stock Crosses Above Two Hundred Day Moving Average of $0.90

DURECT Co. (NASDAQ:DRRXGet Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.90 and traded as high as $1.57. DURECT shares last traded at $1.52, with a volume of 103,106 shares changing hands.

Wall Street Analysts Forecast Growth

DRRX has been the topic of several research analyst reports. Oppenheimer restated an “outperform” rating and issued a $5.00 price objective on shares of DURECT in a research report on Monday, April 1st. HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Wednesday, May 22nd. Finally, StockNews.com upgraded DURECT from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.50.

Check Out Our Latest Report on DRRX

DURECT Stock Down 3.2 %

The firm has a fifty day moving average price of $1.08 and a two-hundred day moving average price of $0.90. The stock has a market capitalization of $47.18 million, a P/E ratio of -1.60 and a beta of 1.12.

DURECT (NASDAQ:DRRXGet Free Report) last released its quarterly earnings data on Monday, May 13th. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). DURECT had a negative return on equity of 328.25% and a negative net margin of 279.77%. The business had revenue of $1.83 million during the quarter, compared to the consensus estimate of $2.73 million. Sell-side analysts anticipate that DURECT Co. will post -0.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DURECT

Hedge funds have recently bought and sold shares of the business. Gagnon Securities LLC grew its stake in shares of DURECT by 6.0% during the 1st quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock valued at $460,000 after purchasing an additional 21,425 shares during the period. Tocqueville Asset Management L.P. grew its stake in shares of DURECT by 10.8% during the 1st quarter. Tocqueville Asset Management L.P. now owns 256,220 shares of the specialty pharmaceutical company’s stock valued at $310,000 after purchasing an additional 25,000 shares during the period. Jump Financial LLC bought a new stake in shares of DURECT during the 3rd quarter valued at about $64,000. Barclays PLC grew its stake in shares of DURECT by 3,366.7% during the 3rd quarter. Barclays PLC now owns 41,600 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 40,400 shares during the period. Finally, Silverberg Bernstein Capital Management LLC bought a new stake in shares of DURECT during the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 28.03% of the company’s stock.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

See Also

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.